However, we and others have demonstrated previously that IL-2, when combined with a tumor-targeting antibody, can achieve exposure-dependent tumor control mediated by local stimulation of cytotoxic CD8+ T and NK cells29,40–43. This evidence concerns the gene CD8A and neoplasm.